Grey
Brand Name(s):Imbruvica
Indication:Chronic lymphocytic leukaemia (CLL)
Rationale:2
Considered:Nov-14
Review Date:Jul-22
Comments:
Drug Safety Update
Reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections
Aug 17
…………………………
NICE TA452
NICE is unable to make a recommendation about the use in the NHS of ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation because no evidence submission was received from JanssenâCilag
Jul-17
…………………………
NICE TA429
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Jan-17